drugset
drugset / Trial / NCT04049903

Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid Tumors

NCT04049903 ↗

Phase 1 Completed 38 enrolled Molecular Partners AG
Non-randomizedSequentialOpen-labelTreatment

Summary

To evaluate the safety and tolerability of MP0310, a DARPin® therapeutic candidate for tumor targeted activation of T cells, in patients with advanced solid tumors

Timeline

Start
2019-09-02
Primary completion
2022-06-27
Completion
2022-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject MP0310 Protein / enzyme biologic — —

Indications

neoplasm